(Q47794879)

5 February 2018

title

HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder (English)

1 reference

5 February 2018

transitional cell carcinoma

1 reference

1 reference

Christopher L Coogan

1

1 reference

5 February 2018

Carlos R Estrada

series ordinal

2

1 reference

5 February 2018

Shiv Kapur

series ordinal

3

1 reference

5 February 2018

Kenneth J Bloom

series ordinal

4

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 April 2004

1 reference

5 February 2018

published in

Urology

1 reference

5 February 2018

volume

63

1 reference

5 February 2018

issue

4

1 reference

5 February 2018

page(s)

786-790

1 reference

5 February 2018

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

1 reference

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

HER-2--a possible target for therapy of metastatic urinary bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.040

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLOGY.2003.10.040

1 reference

5 February 2018

1 reference

5 February 2018